Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3-4/2011

01-12-2011

Autotaxin and LPA receptor signaling in cancer

Authors: Anna J. S. Houben, Wouter H. Moolenaar

Published in: Cancer and Metastasis Reviews | Issue 3-4/2011

Login to get access

Abstract

Lysophosphatidic acid (LPA; monoacyl-glycerol-3-phosphate) is a lipid mediator that functions as a mitogen and motility factor for many cell types. LPA signals through six specific G protein-coupled receptors, named LPA1–6, which trigger both overlapping and distinct signaling pathways. LPA is produced from extracellular lysophosphatidylcholine by a secreted lysophospholipase D, named autotaxin (ATX), originally identified as an “autocrine motility factor” for tumor cells. ATX–LPA signaling is vital for embryonic development and promotes tumor formation, angiogenesis, and experimental metastasis in mice. Elevated expression of ATX and/or aberrant expression of LPA receptors are found in several human malignancies, while loss of LPA6 function has been implicated in bladder cancer. In this review, we summarize our present understanding of ATX and LPA receptor signaling in cancer.
Literature
1.
Choi, J. W., Herr, D. R., Noguchi, K., Yung, Y. C., Lee, C. W., Mutoh, T., et al. (2010). LPA receptors: subtypes and biological actions. Annual Review of Pharmacology and Toxicology, 50, 157–186.PubMedCrossRef
2.
Moolenaar, W. H., van Meeteren, L. A., & Giepmans, B. N. (2004). The ins and outs of lysophosphatidic acid signaling. Bioessays, 26, 870–881.PubMedCrossRef
3.
Tokumura, A., Majima, E., Kariya, Y., Tominaga, K., Kogure, K., Yasuda, K., et al. (2002). Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. Journal of Biological Chemistry, 277, 39436–39442.PubMedCrossRef
4.
Umezu-Goto, M., Kishi, Y., Taira, A., Hama, K., Dohmae, N., Takio, K., et al. (2002). Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. The Journal of Cell Biology, 158, 227–233.PubMedCrossRef
5.
Stracke, M. L., Krutzsch, H. C., Unsworth, E. J., Arestad, A., Cioce, V., Schiffmann, E., et al. (1992). Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. Journal of Biological Chemistry, 267, 2524–2529.PubMed
6.
Chun, J., Hla, T., Lynch, K. R., Spiegel, S., & Moolenaar, W. H. (2010). International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacological Reviews, 62, 579–587.PubMedCrossRef
7.
Mills, G. B., & Moolenaar, W. H. (2003). The emerging role of LPA in cancer. Nature Reviews Cancer, 3, 582–591.PubMedCrossRef
8.
van Corven, E. J., Hordijk, P. L., Medema, R. H., Bos, J. L., & Moolenaar, W. H. (1993). Pertussis toxin-sensitive activation of p21ras by G protein-coupled receptor agonists in fibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 90, 1257–1261.PubMedCrossRef
9.
Kranenburg, O., & Moolenaar, W. H. (2001). Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists. Oncogene, 20, 1540–1546.PubMedCrossRef
10.
Guillermet-Guibert, J., Bjorklof, K., Salpekar, A., Gonella, C., Ramadani, F., Bilancio, A., et al. (2008). The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proceedings of the National Academy of Sciences of the United States of America, 105, 8292–8297.PubMedCrossRef
11.
Kranenburg, O., Poland, M., van Horck, F. P., Drechsel, D., Hall, A., & Moolenaar, W. H. (1999). Activation of RhoA by lysophosphatidic acid and Galpha12/13 subunits in neuronal cells: induction of neurite retraction. Molecular Biology of the Cell, 10, 1851–1857.PubMed
12.
Stam, J. C., Michiels, F., van der Kammen, R. A., Moolenaar, W. H., & Collard, J. G. (1998). Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. EMBO Journal, 17, 4066–4074.PubMedCrossRef
13.
van Leeuwen, F. N., Olivo, C., Grivell, S., Giepmans, B. N., Collard, J. G., & Moolenaar, W. H. (2003). Rac activation by lysophosphatidic acid LPA1 receptors through the guanine nucleotide exchange factor Tiam1. Journal of Biological Chemistry, 278, 400–406.PubMedCrossRef
14.
van Corven, E. J., Groenink, A., Jalink, K., Eichholtz, T., & Moolenaar, W. H. (1989). Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell, 59, 45–54.PubMedCrossRef
15.
Jalink, K., van Corven, E. J., & Moolenaar, W. H. (1990). Lysophosphatidic acid, but not phosphatidic acid, is a potent Ca2(+)-mobilizing stimulus for fibroblasts. Evidence for an extracellular site of action. Journal of Biological Chemistry, 265, 12232–12239.PubMed
16.
Stortelers, C., Kerkhoven, R., & Moolenaar, W. H. (2008). Multiple actions of lysophosphatidic acid on fibroblasts revealed by transcriptional profiling. BMC Genomics, 9, 387.PubMedCrossRef
17.
Harper, K., Arsenault, D., Boulay-Jean, S., Lauzier, A., Lucien, F., & Dubois, C. M. (2010). Autotaxin promotes cancer invasion via the lysophosphatidic acid receptor 4: participation of the cyclic AMP/EPAC/Rac1 signaling pathway in invadopodia formation. Cancer Research, 70, 4634–4643.PubMedCrossRef
18.
Lee, Z., Cheng, C. T., Zhang, H., Subler, M. A., Wu, J., Mukherjee, A., et al. (2008). Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Molecular Biology of the Cell, 19, 5435–5445.PubMedCrossRef
19.
Stefan, C., Jansen, S., & Bollen, M. (2005). NPP-type ectophosphodiesterases: unity in diversity. Trends in Biochemical Sciences, 30, 542–550.PubMedCrossRef
20.
van Meeteren, L. A., & Moolenaar, W. H. (2007). Regulation and biological activities of the autotaxin-LPA axis. Progress in Lipid Research, 46, 145–160.PubMedCrossRef
21.
Kanda, H., Newton, R., Klein, R., Morita, Y., Gunn, M. D., & Rosen, S. D. (2008). Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nature Immunology, 9, 415–423.PubMedCrossRef
22.
Dusaulcy, R., Rancoule, C., Gres, S., Wanecq, E., Colom, A., Guigne, C., et al. (2011). Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. Journal of Lipid Research, 52(6), 1247–1255.PubMedCrossRef
23.
van Meeteren, L. A., Ruurs, P., Christodoulou, E., Goding, J. W., Takakusa, H., Kikuchi, K., et al. (2005). Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. Journal of Biological Chemistry, 280, 21155–21161.PubMedCrossRef
24.
Nishimasu, H., Okudaira, S., Hama, K., Mihara, E., Dohmae, N., Inoue, A., et al. (2011). Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nature Structural and Molecular Biology, 18, 205–212.PubMedCrossRef
25.
Hausmann, J., Kamtekar, S., Christodoulou, E., Day, J. E., Wu, T., Fulkerson, Z., et al. (2011). Structural basis of substrate discrimination and integrin binding by autotaxin. Nature Structural and Molecular Biology, 18, 198–204.PubMedCrossRef
26.
Pamuklar, Z., Federico, L., Liu, S., Umezu-Goto, M., Dong, A., Panchatcharam, M., et al. (2009). Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. Journal of Biological Chemistry, 284, 7385–7394.PubMedCrossRef
27.
van Meeteren, L. A., Ruurs, P., Stortelers, C., Bouwman, P., van Rooijen, M. A., Pradere, J. P., et al. (2006). Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Molecular and Cellular Biology, 26, 5015–5022.PubMedCrossRef
28.
Tanaka, M., Okudaira, S., Kishi, Y., Ohkawa, R., Iseki, S., Ota, M., et al. (2006). Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. Journal of Biological Chemistry, 281, 25822–25830.PubMedCrossRef
29.
Fotopoulou, S., Oikonomou, N., Grigorieva, E., Nikitopoulou, I., Paparountas, T., Thanassopoulou, A., et al. (2010). ATX expression and LPA signalling are vital for the development of the nervous system. Dev Biol, 339, 451–464.PubMedCrossRef
30.
Koike, S., Keino-Masu, K., & Masu, M. (2010). Deficiency of autotaxin/lysophospholipase D results in head cavity formation in mouse embryos through the LPA receptor-Rho-ROCK pathway. Biochemical and Biophysical Research Communications, 400, 66–71.PubMedCrossRef
31.
Matas-Rico, E., Garcia-Diaz, B., Llebrez-Zayas, P., Lopez-Barroso, D., Santin, L., Pedraza, C., et al. (2008). Deletion of lysophosphatidic acid receptor LPA1 reduces neurogenesis in the mouse dentate gyrus. Molecular and Cellular Neuroscience, 39, 342–355.PubMedCrossRef
32.
Gennero, I., Laurencin-Dalicieux, S., Conte-Auriol, F., Briand-Mesange, F., Laurencin, D., Rue, J., et al. (2011). Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass. Bone, 49(3), 395–403.PubMedCrossRef
33.
Ye, X., Hama, K., Contos, J. J., Anliker, B., Inoue, A., Skinner, M. K., et al. (2005). LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature, 435, 104–108.PubMedCrossRef
34.
Sumida, H., Noguchi, K., Kihara, Y., Abe, M., Yanagida, K., Hamano, F., et al. (2010). LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis. Blood, 116, 5060–5070.PubMedCrossRef
35.
Contos, J. J., Ishii, I., Fukushima, N., Kingsbury, M. A., Ye, X., Kawamura, S., et al. (2002). Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Molecular and Cellular Biology, 22, 6921–6929.PubMedCrossRef
36.
Kawagoe, H., Stracke, M. L., Nakamura, H., & Sano, K. (1997). Expression and transcriptional regulation of the PD-Ialpha/autotaxin gene in neuroblastoma. Cancer Research, 57, 2516–2521.PubMed
37.
Zhang, G., Zhao, Z., Xu, S., Ni, L., & Wang, X. (1999). Expression of autotaxin mRNA in human hepatocellular carcinoma. Chinese Medical Journal, 112, 330–332.PubMed
38.
Yang, S. Y., Lee, J., Park, C. G., Kim, S., Hong, S., Chung, H. C., et al. (2002). Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clinical & Experimental Metastasis, 19, 603–608.CrossRef
39.
Stassar, M. J., Devitt, G., Brosius, M., Rinnab, L., Prang, J., Schradin, T., et al. (2001). Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. British Journal of Cancer, 85, 1372–1382.PubMedCrossRef
40.
Hoelzinger, D. B., Mariani, L., Weis, J., Woyke, T., Berens, T. J., McDonough, W. S., et al. (2005). Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia, 7, 7–16.PubMedCrossRef
41.
Yang, Y., Mou, L., Liu, N., & Tsao, M. S. (1999). Autotaxin expression in non-small-cell lung cancer. American Journal of Respiratory Cell and Molecular Biology, 21, 216–222.PubMed
42.
Baumforth, K. R., Flavell, J. R., Reynolds, G. M., Davies, G., Pettit, T. R., Wei, W., et al. (2005). Induction of autotaxin by the Epstein–Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood, 106, 2138–2146.PubMedCrossRef
43.
Masuda, A., Nakamura, K., Izutsu, K., Igarashi, K., Ohkawa, R., Jona, M., et al. (2008). Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. British Journal of Haematology, 143, 60–70.PubMedCrossRef
44.
Kehlen, A., Englert, N., Seifert, A., Klonisch, T., Dralle, H., Langner, J., et al. (2004). Expression, regulation and function of autotaxin in thyroid carcinomas. International Journal of Cancer, 109, 833–838.CrossRef
45.
Nam, S. W., Clair, T., Kim, Y. S., McMarlin, A., Schiffmann, E., Liotta, L. A., et al. (2001). Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Research, 61, 6938–6944.PubMed
46.
Black, E. J., Clair, T., Delrow, J., Neiman, P., & Gillespie, D. A. (2004). Microarray analysis identifies autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun. Oncogene, 23, 2357–2366.PubMedCrossRef
47.
Zirn, B., Samans, B., Wittmann, S., Pietsch, T., Leuschner, I., Graf, N., et al. (2006). Target genes of the WNT/beta-catenin pathway in Wilms tumors. Genes, Chromosomes & Cancer, 45, 565–574.CrossRef
48.
Tice, D. A., Szeto, W., Soloviev, I., Rubinfeld, B., Fong, S. E., Dugger, D. L., et al. (2002). Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling. Journal of Biological Chemistry, 277, 14329–14335.PubMedCrossRef
49.
Dufner-Beattie, J., Lemons, R. S., & Thorburn, A. (2001). Retinoic acid-induced expression of autotaxin in N-myc-amplified neuroblastoma cells. Molecular Carcinogenesis, 30, 181–189.PubMedCrossRef
50.
Zirn, B., Samans, B., Spangenberg, C., Graf, N., Eilers, M., & Gessler, M. (2005). All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene, 24, 5246–5251.PubMedCrossRef
51.
Chen, M., & O’Connor, K. L. (2005). Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. Oncogene, 24, 5125–5130.PubMedCrossRef
52.
Nam, S. W., Clair, T., Campo, C. K., Lee, H. Y., Liotta, L. A., & Stracke, M. L. (2000). Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene, 19, 241–247.PubMedCrossRef
53.
Boucharaba, A., Serre, C. M., Gres, S., Saulnier-Blache, J. S., Bordet, J. C., Guglielmi, J., et al. (2004). Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. The Journal of Clinical Investigation, 114, 1714–1725.PubMed
54.
Boucharaba, A., Serre, C. M., Guglielmi, J., Bordet, J. C., Clezardin, P., & Peyruchaud, O. (2006). The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proceedings of the National Academy of Sciences of the United States of America, 103, 9643–9648.PubMedCrossRef
55.
David, M., Wannecq, E., Descotes, F., Jansen, S., Deux, B., Ribeiro, J., et al. (2010). Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One, 5, e9741.PubMedCrossRef
56.
Yu, S., Murph, M. M., Lu, Y., Liu, S., Hall, H. S., Liu, J., et al. (2008). Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. Journal of the National Cancer Institute, 100, 1630–1642.PubMedCrossRef
57.
Taghavi, P., Verhoeven, E., Jacobs, J. J., Lambooij, J. P., Stortelers, C., Tanger, E., et al. (2008). In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. Oncogene, 27, 6806–6816.PubMedCrossRef
58.
Liu, S., Umezu-Goto, M., Murph, M., Lu, Y., Liu, W., Zhang, F., et al. (2009). Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell, 15, 539–550.PubMedCrossRef
59.
Lin, S., Wang, D., Iyer, S., Ghaleb, A. M., Shim, H., Yang, V. W., et al. (2009). The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology, 136, 1711–1720.PubMedCrossRef
60.
Lin, S., Lee, S. J., Shim, H., Chun, J., & Yun, C. C. (2010). The absence of LPA receptor 2 reduces the tumorigenesis by Apc Min mutation in the intestine. American Journal of Physiology. Gastrointestinal and Liver Physiology, 299, G1128–G1138.PubMedCrossRef
61.
Nakai, Y., Ikeda, H., Nakamura, K., Kume, Y., Fujishiro, M., Sasahira, N., et al. (2011). Specific increase in serum autotaxin activity in patients with pancreatic cancer. Clinical Biochemistry, 44(8–9), 576–581.PubMedCrossRef
62.
Lu, Y., Lemon, W., Liu, P. Y., Yi, Y., Morrison, C., Yang, P., et al. (2006). A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Medicine, 3, e467.PubMedCrossRef
63.
Lee, S., Jeong, J., Majewski, T., Scherer, S. E., Kim, M. S., Tuziak, T., et al. (2007). Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proceedings of the National Academy of Sciences of the United States of America, 104, 13732–13737.PubMedCrossRef
64.
Pasternack, S. M., von Kugelgen, I., Aboud, K. A., Lee, Y. A., Ruschendorf, F., Voss, K., et al. (2008). G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nature Genetics, 40, 329–334.PubMedCrossRef
65.
Yanagida, K., Masago, K., Nakanishi, H., Kihara, Y., Hamano, F., Tajima, Y., et al. (2009). Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. Journal of Biological Chemistry, 284(26), 17731–17741.PubMedCrossRef
66.
Kaplan, M. H., Smith, D. I., & Sundick, R. S. (1993). Identification of a G protein coupled receptor induced in activated T cells. Journal of Immunology, 151, 628–636.
67.
Majewski, T., Lee, S., Jeong, J., Yoon, D. S., Kram, A., Kim, M. S., et al. (2008). Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Laboratory Investigation, 88, 694–721.PubMedCrossRef
68.
Song, H., Ramus, S. J., Shadforth, D., Quaye, L., Kjaer, S. K., Dicioccio, R. A., et al. (2006). Common variants in RB1 gene and risk of invasive ovarian cancer. Cancer Research, 66, 10220–10226.PubMedCrossRef
69.
Kazantseva, A., Goltsov, A., Zinchenko, R., Grigorenko, A. P., Abrukova, A. V., Moliaka, Y. K., et al. (2006). Human hair growth deficiency is linked to a genetic defect in the phospholipase gene LIPH. Science, 314, 982–985.PubMedCrossRef
70.
71.
Baker, D. L., Fujiwara, Y., Pigg, K. R., Tsukahara, R., Kobayashi, S., Murofushi, H., et al. (2006). Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. Journal of Biological Chemistry, 281, 22786–22793.PubMedCrossRef
72.
Durgam, G. G., Virag, T., Walker, M. D., Tsukahara, R., Yasuda, S., Liliom, K., et al. (2005). Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. Journal of Medicinal Chemistry, 48, 4919–4930.PubMedCrossRef
73.
Zhang, H., Xu, X., Gajewiak, J., Tsukahara, R., Fujiwara, Y., Liu, J., et al. (2009). Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Research, 69, 5441–5449.PubMedCrossRef
74.
van Meeteren, L. A., Brinkmann, V., Saulnier-Blache, J. S., Lynch, K. R., & Moolenaar, W. H. (2008). Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D. Cancer Letters, 266, 203–208.PubMedCrossRef
75.
Gupte, R., Patil, R., Liu, J., Wang, Y., Lee, S. C., Fujiwara, Y., et al. (2011). Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity. ChemMedChem, 6, 922–935.PubMedCrossRef
76.
Albers, H. M., Dong, A., van Meeteren, L. A., Egan, D. A., Sunkara, M., van Tilburg, E. W., et al. (2010). Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proceedings of the National Academy of Sciences of the United States of America, 107, 7257–7262.PubMedCrossRef
77.
Albers, H. M., van Meeteren, L. A., Egan, D. A., van Tilburg, E. W., Moolenaar, W. H., & Ovaa, H. (2010). Discovery and optimization of boronic acid based inhibitors of autotaxin. Journal of Medicinal Chemistry, 53, 4958–4967.PubMedCrossRef
78.
Gierse, J., Thorarensen, A., Beltey, K., Bradshaw-Pierce, E., Cortes-Burgos, L., Hall, T., et al. (2010). A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. Journal of Pharmacology and Experimental Therapeutics, 334, 310–317.PubMedCrossRef
Metadata
Title
Autotaxin and LPA receptor signaling in cancer
Authors
Anna J. S. Houben
Wouter H. Moolenaar
Publication date
01-12-2011
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3-4/2011
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-011-9319-7

Other articles of this Issue 3-4/2011

Cancer and Metastasis Reviews 3-4/2011 Go to the issue

OriginalPaper

EET signaling in cancer

OriginalPaper

Hepoxilins in cancer and inflammation—use of hepoxilin antagonists

OriginalPaper

Basic aspects of tumor cell fatty acid-regulated signaling and transcription factors

OriginalPaper

The cytochrome P450 pathway in angiogenesis and endothelial cell biology

OriginalPaper

Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence

OriginalPaper

Essential fatty acids and their metabolites as modulators of stem cell biology with reference to inflammation, cancer, and metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits